Protocol - Substances - 30-Day Frequency
Measurement of respondent’s 30-day frequency of use of drugs.
The Working Group acknowledges that the following question may gather sensitive information relating to the use of substances or illegal conduct. If the information is released, it might be damaging to an individual’s employability, lead to social stigmatization, or result in other consequences.
For information on obtaining a Certificate of Confidentiality, which helps researchers protect the privacy of human research participants, please go to the National Human Genome Research Institute’s Institutional Review Board website.
Respondents are asked the 30-day frequency question only if they answered "yes" to a drug in the Substances - Lifetime Use measure. For example, if a respondent said he or she had ever used marijuana, he or she will be asked the 30-day question for marijuana. Investigators should refer back to the substance(s) indicated in the Substances - Lifetime Use measure when asking the below question. The drug categories are provided below:
- Sedatives or tranquilizers
- Cocaine or crack
- Club drugs
- Inhalants or solvents
Respondents can refer to the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) flashcard that provides examples of each.
TYPES OF MEDICINES/DRUGS
1 Sedatives or tranquilizers, for example…barbs, downers, Ambien, Lunesta, phenobarbital, pentobarbital, Halcion, Tuinal, Nembutal, Seconal, Librium, Valium, Xanax, benzodiazepines, tranks, Ativan.
2 Painkillers, for example…methadone, codeine, Demerol, Vicodin, OxyContin, opium, oxy, Percocet, Dilaudid, Percodan, morphine
3 Marijuana, including THC, for example…weed, pot, dope, hashish, Mary Jane, joint, blunt
4 Cocaine or crack, for example…blow, rock, snow
5 Stimulants, for example…Adderall, Concerta, Cylert, Provigil, Ritalin or Dexedrine, speed, amphetamine, methamphetamine, uppers, bennies, pep pills, crystal, crank
6 Club drugs, for example…MDMA, ecstasy, GHB, Rohypnol, ketamine, Special K, XTC, roofies
7 Hallucinogens, for example…LSD, acid, PCP, mescaline, peyote, psilocybin, mushrooms, angel dust, cactus
8 Inhalants or solvents, for example…nitrous oxide, lighter fluid, gasoline, cleaning fluid, glue, poppers, whippets
9 Heroin, for example…smack, black tar, poppy
10 Any OTHER medicines
- Think specifically about the past 30 days, from [DATEFILL**] up to and including today. During the past 30 days, on how many days did you use…?
# OF DAYS: _________ [RANGE: 0-30]
[ ] DK/REF
SHOW 30 DAY CALENDAR
Personnel and Training Required
Interviewer must be trained and found competent to conduct personal interviews with individuals from the general population. The interviewer should be trained to prompt respondents further if a "don’t know" response is provided.
While the source instrument was developed for administration by computer, the PhenX Expert Review Panel acknowledges that these questions can be administered in a noncomputerized format.
|Specialized requirements for biospecimen collection||No|
|Average time of greater than 15 minutes in an unaffected individual||No|
Mode of Administration
18 years of age or older
The protocol from the 2015 National Survey on Drug Use and Health (NSDUH) was chosen because it is a large nationally representative study. The measures from this survey have been validated and psychometrically tested.
English, Other languages available at source
|caDSR Form||PhenX PX031302 - Substances 30day Frequency||6910301||caDSR Form|
Process and Review
The Expert Review Panel #3 (ERP 3) reviewed the measures in Alcohol, Tobacco and Other Substances, and Substance Abuse and Addiction domains.
Guidance from ERP 3 includes:
Updated version of protocol available.
• Updated protocol
• New Data Dictionary
Back-compatible: Partially back-compatible (updated/similar protocol which would require some changes to the data dictionary), variable mapping between current and previous protocols can be found here.
Previous version in Toolkit archive (link)
Protocol Name from Source
National Survey on Drug Use and Health (NSDUH), 2015
Substance Abuse and Mental Health Services Administration. (2015, February). National Survey on Drug Use and Health (NSDUH), 2015. Rockville, MD: Author. CAI Specifications for Programming, English Version.
|Variable Name||Variable ID||Variable Description||dbGaP Mapping|
|PX031302010100||Think specifically about the past 30 days, more||Variable Mapping|
|PX031302010200||Think specifically about the past 30 days, more||N/A|
Substances - 30-Day Frequency
November 21, 2016
Questions asking the respondent how many days in the past 30 days he or she used a drug.
This measure can be used to assess the participant’s recent consumption of a substance. The potential of recall bias can be reduced by assessing the respondent’s recent use.
substances - 30-day frequency, Drugs, substance use, illicit substances, cannabis, marijuana, THC, hashish, LSD, acid, PCP, angel dust, phencyclidine, peyote, mescaline, psilocybin, ecstasy, MDMA, sedative, tranquilizer, pain reliever, stimulant, prescription drug, cocaine, crack cocaine, hallucinogen, inhalant, solvent, heroin, methamphetamine, substance abuse and addiction, SAA, National Survey on Drug Use and Health, NSDUH, gerontology, aging, geriatrics
|Protocol ID||Protocol Name|
|31301||Substances - 30-Day Frequency|
|31302||Substances - 30-Day Frequency|
Sarfan, L. D., et al. (2023) The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) for serious mental illness in community mental health part 1: study protocol for a hybrid type 2 effectiveness-implementation cluster-randomized trial. Trials. 2023 March; 24(1): 198. doi: 10.1186/s13063-023-07148-9
Phillips, K. A., et al. (2017) Current drug users and women have higher rates of risky sexual behaviors. Drug and Alcohol Dependence. 2017 February; 171: e165-e166. doi: 10.1016/j.drugalcdep.2016.08.455
Pattaro, C., et al. (2015) The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. J Transl Med. 2015 November; 13: 348. doi: 10.1186/s12967-015-0704-9